» Articles » PMID: 17557911

Inhibition of Mitochondrial Permeability Transition Improves Functional Recovery and Reduces Mortality Following Acute Myocardial Infarction in Mice

Overview
Date 2007 Jun 15
PMID 17557911
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Inhibition of mitochondrial permeability transition pore (mPTP) opening by cyclosporin A or ischemic postconditioning attenuates lethal reperfusion injury. Its impact on major post-myocardial infarction events, including worsening of left ventricular (LV) function and death, remains unknown. We sought to determine whether pharmacological or postconditioning-induced inhibition of mPTP opening might improve functional recovery and survival following myocardial infarction in mice. Anesthetized mice underwent 25 min of ischemia and 24 h (protocol 1) or 30 days (protocol 2) of reperfusion. At reperfusion, they received no intervention (control), postconditioning (3 cycles of 1 min ischemia-1 min reperfusion), or intravenous injection of the mPTP inhibitor Debio-025 (10 mg/kg). At 24 h of reperfusion, mitochondria were isolated from the region at risk for assessment of the Ca(2+) retention capacity (CRC). Infarct size was measured by triphenyltetrazolium chloride staining. At 30 days of reperfusion, mortality and LV contractile function (echocardiography) were evaluated. Postconditioning and Debio-025 significantly improved Ca(2+) retention capacity (132 +/- 13 and 153 +/- 31 vs. 53 +/- 16 nmol Ca(2+)/mg protein in control) and reduced infarct size to 35 +/- 4 and 32 +/- 7% of area at risk vs. 61 +/- 6% in control (P < 0.05). At 30 days, ejection fraction averaged 74 +/- 6 and 77 +/- 6% in postconditioned and Debio-025 groups, respectively, vs. 62 +/- 12% in the control group (P < 0.05). At 30 days, survival was improved from 58% in the control group to 92 and 89% in postconditioned and Debio-025 groups, respectively. Inhibition of mitochondrial permeability transition at reperfusion improves functional recovery and mortality in mice.

Citing Articles

Cardiovascular protection of YiyiFuzi powder and the potential mechanisms through modulating mitochondria-endoplasmic reticulum interactions.

Ding J, Ji R, Wang Z, Jia Y, Meng T, Song X Front Pharmacol. 2024; 15:1405545.

PMID: 38978978 PMC: 11228702. DOI: 10.3389/fphar.2024.1405545.


The novel cyclophilin inhibitor C105SR reduces hepatic ischaemia-reperfusion injury via mitoprotection.

Kheyar A, Ahnou N, Ahmed-Belkacem A, Hulin A, Pressiat C, Ghaleh B JHEP Rep. 2023; 5(11):100876.

PMID: 37860051 PMC: 10582583. DOI: 10.1016/j.jhepr.2023.100876.


Mitochondrial Volume Regulation and Swelling Mechanisms in Cardiomyocytes.

Chapa-Dubocq X, Rodriguez-Graciani K, Escobales N, Javadov S Antioxidants (Basel). 2023; 12(8).

PMID: 37627512 PMC: 10451443. DOI: 10.3390/antiox12081517.


Targeting Artemisinin-Resistant Malaria by Repurposing the Anti-Hepatitis C Virus Drug Alisporivir.

Chaurasiya A, Kumari G, Garg S, Shoaib R, Anam Z, Joshi N Antimicrob Agents Chemother. 2022; 66(12):e0039222.

PMID: 36374050 PMC: 9765015. DOI: 10.1128/aac.00392-22.


Dichloroacetate as a metabolic modulator of heart mitochondrial proteome under conditions of reduced oxygen utilization.

Andelova N, Waczulikova I, Kunstek L, Talian I, Ravingerova T, Jasova M Sci Rep. 2022; 12(1):16348.

PMID: 36175475 PMC: 9522880. DOI: 10.1038/s41598-022-20696-5.